Aminoglycosides: How should we use them in the 21st century?

Current Opinion in Infectious Diseases

Volumn 26, Issue 6, 2013, Pages 516-525

  Jackson, Justin ^a   Chen, Caroline ^b   Buising, Kirsty ^a,b,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

aminoglycosides; endocarditis; gentamicin; Gram negative; sepsis; vestibular toxicity

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOGLYCOSIDE MODIFYING ENZYME; AMPICILLIN; APRAMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEMASE; CEFTRIAXONE; COLISTIN; COTRIMOXAZOLE; ENZYME; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; GENTAMICIN BONE CEMENT; HABEKACIN; KANAMYCIN; NEOMYCIN; NETILMICIN; PAROMOMYCIN; PENICILLIN G; PLAZOMICIN; POLYMYXIN; RNA 16S; RNA METHYLTRANSFERASE; SISOMICIN; STREPTOMYCIN; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTINOMYCETALES INFECTION; AMEBIASIS; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; AWARENESS; BACTEREMIA; BACTERIAL ENDOCARDITIS; CLINICAL PRACTICE; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; ENTEROCOCCAL INFECTION; EPIDEMIC; GIARDIASIS; GRAM NEGATIVE INFECTION; HEARING IMPAIRMENT; HUMAN; INFECTION PREVENTION; INFECTIOUS ARTHRITIS; INNER EAR DISEASE; MENINGOENCEPHALITIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIOSIS; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NOCARDIOSIS; OTOTOXICITY; POLYPHARMACY; PROSTHESIS INFECTION; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; SKIN LEISHMANIASIS; STREPTOCOCCUS INFECTION; SURGICAL INFECTION; TREATMENT DURATION; VESTIBULAR DISORDER; VESTIBULAR SYSTEM; VISCERAL LEISHMANIASIS; ZOONOSIS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 84887321144     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000012     Document Type: Review

References (122)

1. Kotra LP, Haddad J, Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 2000; 44:3249-3256.
2. Taber HW, Mueller J, Miller P, Arrow A. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev 1987; 51:439-457.
3. Jana S, Deb J. Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol 2006; 70:140-150.
4. Bryan L, Kwan S. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob Agents Chemother 1983; 23:835-845.
5. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010; 13:151-171.
6. Becker B, Cooper MA. Aminoglycoside antibiotics in the 21st century. ACS Chem Biol 2012; 8:105-115. An excellent review on aminoglycosides, focusing on resistance mechanisms.
7. Kohanski MA, Dwyer DJ, Wierzbowski J, et al. Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cell 2008; 135:679-690.
8. Prammananan T, Sander P, Brown BA, et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis 1998; 177:1573-1581.
9. Nessar R, Reyrat JM, Murray A, Gicquel B. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother 2011; 66:1719-1724.
10. Li X-Z, Nikaido H, Poole K. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39:1948-1953.
11. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:479-487.
12. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56:20-51.
13. Chiang W-C, Nilsson M, Jensen P\O, et al. Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2013; 57:2352-2361
14. Jia X, Zhang J, Sun W, et al. Riboswitch control of aminoglycoside antibiotic resistance. Cell 2013; 152:68-81.
15. Ramirez MS, Nikolaidis N, Tolmasky ME. Rise and dissemination of aminoglycoside resistance: the aac (60)-Ib paradigm. Front Microbiol 2013; 4:121
16. Hanberger H, Edlund C, Furebring M, et al. Rational use of aminoglycosides-review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scand J Infect Dis 2013; 45:161-175
17. Lu P-L, Liu Y-C, Toh H-S, et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2012; 40:S37-S43.
18. Babinchak T, Badal R, Hoban D, et al. Trends in susceptibility of selected Gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010. Diagn Microbiol Infect Dis 2013; 76:379-381.
19. Bouchillon SK, Badal RE, Hoban DJ, Hawser SP. Antimicrobial susceptibility of inpatient urinary tract isolates of Gram-negative bacilli in the United States: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program: 2009-2011. Clin Ther 2013; 35:872-877.
20. Livermore DM. Current epidemiology and growing resistance of Gramnegative pathogens. Korean J Intern Med 2012; 27:128-142.
21. Fritsche TR, Castanheira M, Miller GH, et al. Detection of methyltransferases conferring high-level resistance to aminoglycosides in Enterobacteriaceae from Europe, North America, and Latin America. Antimicrob Agents Chemother 2008; 52:1843-1845.
22. Jiang Y, Yu D, Wei Z, et al. Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA. Antimicrob Agents Chemother 2010; 54:3967-3969.
23. Wachino J, Arakawa Y. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. Drug Resist Updat 2012; 15:133-148.
24. Jensen-Smith HC, Hallworth R, Nichols MG. Gentamicin rapidly inhibits mitochondrial metabolism in high-frequency cochlear outer hair cells. PloS ONE 2012; 7:e38471.
25. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Pharmacogenomics 2005; 6:27-36.
26. Seddon JA, Godfrey-Faussett P, Jacobs K, et al. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 2012; 40:1277-1286.
27. Harris T, Bardien S, Schaaf HS, et al. Aminoglycoside: induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J 2012; 102:363-365.
28. Chen KS, Bach A, Shoup A, Winick NJ. Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides. Pediatr Blood Cancer 2013; 60:1772-1777.
29. Zimmerman E, Lahav A. Ototoxicity in preterm infants: effects of genetics, aminoglycosides, and loud environmental noise. J Perinatol 2012; 33:3-8.
30. Sha S-H, Qiu J-H, Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med 2006; 354:1856-1857.
31. Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 2007; 72:359-363.
32. Huth M, Alharazneh AM, Ricci A, et al. Gentamicin ototoxicity requires functional mechanotransducer channels. Otolaryngol Head Neck Surgery 2011; 145:94-194.
33. Matt T, Ng CL, Lang K, et al. Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci 2012; 109:10984-10989
34. Minor LB. Gentamicin-induced bilateral vestibular hypofunction. JAMA 1998; 279:541-544.
35. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity-A review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984; 13:9-22.
36. Ariano RE, Zelenitsky SA, Kassum DA. Aminoglycoside-induced vestibular injury: maintaining a sense of balance. Ann Pharmacother 2008; 42:1282-1289.
37. Ahmed RM, Hannigan IP, MacDougall HG, et al. Gentamicin ototoxicity: a 23-year selected case series of 103 patients. Med J Aust 2012; 196:701-
38. This cohort study provides important data on aminoglycoside use and severe vestibular toxicity.
39. Edson RS, Brey RH, McDonald TJ, et al. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clinic Proc 2004; 79:1185-1191.
40. Ahya VN, Doyle AM, Mendez JD, et al. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant 2005; 24:932-935.
41. Chong TK, Piraino B, Bernardini J. Vestibular toxicity due to gentamicin in peritoneal dialysis patients. Perit Dial Int 1991; 11:152-155.
42. Marais J, Rutka J.Ototoxicity and topical eardrops. Clin Otolaryngol Allied Sci 1998; 23:360-367.
43. Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2010; 79:33-45.
44. Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health 2006; 42:601-605.
45. de Klaver PA, Hendriks JG, van Onzenoort HA, et al. Gentamicin serum concentrations in patients with gentamicin-PMMA beads for infected hip joints: a prospective observational cohort study. Ther Drug Monit 2012; 34:67-71.
46. Kalil GZ, Ernst EJ, Johnson SJ, et al. Systemic exposure to aminoglycosides following knee and hip arthroplasty with aminoglycoside-loaded bone cement implants. Ann Pharmacother 2012; 46:929-934.
47. Florescu MC, Lyden E, Murphy PJ, et al. Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis. Hemodial Int 2012; 16:414-419.
48. Pasquale TR, Tan JS. Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 2005; 40:127-135.
49. Sansthan BU. Tetany in kala azar patients treated with paromomycin. Indian J Med Res 2008; 127:489-493.
50. Craig WA. Optimizing aminoglycoside use. Crit Care Clin 2011; 27:107-121.
51. Poulikakos P, Falagas ME. Aminoglycoside therapy in infectious diseases. Expert Opin Pharmacother 2013; 1-13
52. Fetter M. Assessing vestibular function: which tests, when? J Neurol 2000; 247:335-342.
53. Sun H-Y, Fujitani S, Quintiliani R, Victor LY. Pneumonia due to Pseudomonas aeruginosa Part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. CHEST J 2011; 139:1172-1185.
54. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99.
55. Zelenitsky SA, Harding GK, Sun S, et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 2003; 52:668-674.
56. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 2003; 17:503-528.
57. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24:796-809.
58. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24:786-795.
59. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. Br Med J 1996; 312:338-344.
60. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37:645-663.
61. Buchholtz K, Larsen CT, Schaadt B, et al. Once versus twice daily gentamicin dosing for infective endocarditis: a randomized clinical trial. Cardiology 2011; 119:65-71.
62. Dahl A, Rasmussen RV, Bundgaard H, et al. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation 2013; 127:1810-1817
63. Avent M, Rogers B, Cheng A, Paterson D. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J 2011; 41:441-449.
64. Leong C, Buising K, Richards M, et al. Providing guidelines and education is not enough: an audit of gentamicin use at The Royal Melbourne Hospital. Intern Med J 2006; 36:37-42.
65. Hwang J-H, Lee J-H, Moon M-K, et al. The usefulness of arbekacin compared to vancomycin. Eur J Clin Microbiol Infect Dis 2012; 31:1663-1666
66. Savini V, Fazii P, Favaro M, et al. Tuberculosis-like pneumonias by the aerobic actinomycetes Rhodococcus, Tsukamurella and Gordonia. Microbes Infect 2012; 14:401-410.
67. Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin Proc 2012; 87:403-407.
68. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013; 368:745-755.
69. Davidson RN, den Boer M, Ritmeijer K. Paromomycin. Trans R Soc Trop Med Hyg 2009; 103:653-660.
70. Butler T. Plague into the 21st century. Clin Infect Dis 2009; 49:736-742.
71. Rolain J-M, Maurin M, Raoult D. Bactericidal effect of antibiotics on Bartonella and Brucella spp.: clinical implications. J Antimicrob Chemother 2000; 46:811-814.
72. Biswas S, Rolain JM. Bartonella infection: treatment and drug resistance. Future Microbiol 2010; 5:1719-1731.
73. Koruk ST, Erdem H, Koruk I, et al. Management of Brucella endocarditis: results of the Gulhane study. Int J Antimicrob Agents 2012; 40:145-150.
74. Hepburn MJ, Simpson AJ. Tularemia: current diagnosis and treatment options. Expert Rev Anti Infect Ther 2008; 6:231-240.
75. Mwengee W, Butler T, Mgema S, et al. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis 2006; 42:614-621.
76. Jackson J, McGregor A, Cooley L, et al. Francisella tularensis subspecies holarctica, Tasmania, Australia, 2011. Emerg Infect Dis 2012; 18:1484-1486.
77. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013; 368:524-532.
78. Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007; 60:247-257.
79. Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45:753-760.
80. Crabtree TD, Pelletier SJ, Gleason TG, et al. Analysis of aminoglycosides in the treatment of Gram-negative infections in surgical patients. Arch Surg 1999; 134:1293-1298.
81. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactamaminoglycoside combination treatment for Gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127-1133.
82. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701-708.
83. Morata L, Cobos-Trigueros N, Mart?́nez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012; 56:4833-4837.
84. Bailey JA, Virgo KS, DiPiro JT, et al. Aminoglycosides for intra-abdominal infection: equal to the challenge? Surg Infect 2002; 3:315-335.
85. Falagas M, Matthaiou D, Karveli E, Peppas G. Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs. b-lactam monotherapy for the treatment of intra-abdominal infections. Aliment Pharmacol Ther 2007; 25:537-556.
86. Wood M, Farrell W. Comparison of urinary excretion of tobramycin and gentamicin in adults. J Infect Dis 1976; 134:S133-S138.
87. Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenemresistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011; 55:5893-5899.
88. Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of b-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents 2011; 37:491-503.
89. Paul M, Soares-Weiser K, Leibovici L. b-Lactam monotherapy versus b lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br Med J 2003; 326:1111.
90. Pena C, Suarez C, Ocampo-Sosa A, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis 2013; 57:208-216
91. Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. b-Lactam plus aminoglycoside or fluoroquinolone combination versus b-lactam monotherapy for Pseudomonas aeruginosa infections: A meta-analysis. Int J Antimicrob Agents 2013; 41:301-310.
92. Paul M, Leibovici L. Combination therapy for Pseudomonas aeruginosa bacteremia: where do we stand? [editorial commentary]. Clin Infect Dis 2013; 57:217-220
93. Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and blactam combination therapy versus b-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41:149-158.
94. Geraci JE, Martin WJ. Antibiotic therapy of bacterial endocarditis VI. Subacute enterococcal endocarditis: clinical, pathologic and therapeutic consideration of 33 cases. Circulation 1954; 10:173-194.
95. Miro JM, Pericas JM, del Rio A. A new era for treating Enterococcus faecalis endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that is the question! Circulation 2013; 127:1763-1766.
96. Fernández-Hidalgo N, Almirante B, Gavalda J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013; 56:1261-1268
97. Olaison L. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002; 34:159-166.
98. Munita JM, Arias CA, Murray BE. Enterococcus faecalis infective endocarditis: is it time to abandon aminoglycosides? [editorial commentary]. Clin Infect Dis 2013; 56:1269-1272.
99. Solla DJF. Effectiveness of ampicillin plus ceftriaxone compared to ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis: a noninferiority question not yet properly investigated. Clin Infect Dis 2013; 57:768.
100. Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 2009; 63:246-251.
101. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a b-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006; 57:639-647.
102. Cosgrove SE, Vigliani GA, Campion M, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713-721.
103. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394-e434.
104. Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269-289.
105. Merle-Melet M, Dossou-Gbete L, Maurer P, et al. Is amoxicillin- cotrimoxazole the most appropriate antibiotic regimen for listeria meningoencephalitis? Review of 22 cases and the literature. J Infect 1996; 33:79-85.
106. Mitja O, Pigrau C, Ruiz I, et al. Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study. J Antimicrob Chemother 2009; 64:416-423.
107. Challagundla SR, Knox D, Hawkins A, et al. Renal impairment after high-dose flucloxacillin and single-dose gentamicin prophylaxis in patients undergoing elective hip and knee replacement. Nephrol Dial Transplant 2013; 28:612-619
108. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:625-663.
109. Huttner B, Haustein T, Uçkay I, et al. Decolonization of intestinal carriage of extended-spectrum b-lactamase-producing Enterobacteriaceae with oral colistin and neomycin: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 2013; 68:2375-2382.
110. Saidel-Odes L, Polachek H, Peled N, et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 2012; 33:14-19.
111. de Smet AMG, Bonten MJ, Kluytmans JA. For whom should we use selective decontamination of the digestive tract? Curr Opin Infect Dis 2012; 25:211-217
112. Hodson M, Gallagher C, Govan J. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20:658-664.
113. Má iz L, Girón RM, Olveira C, et al. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin Pharmacother 2013; 14:1135-1149.
114. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009; 4:CD004197.
115. Barth RE, Vogely HC, Hoepelman AI, Peters EJ. 'To bead or not to bead?' Treatment of osteomyelitis and prosthetic joint-associated infections with gentamicin bead chains. Int J Antimicrob Agents 2011; 38:371-375.
116. Chang WK, Srinivasa S, MacCormick AD, Hill AG. Gentamicin-collagen implants to reduce surgical site infection: systematic review and metaanalysis of randomized trials. Ann Surg 2013; 258:59-65
117. Sato R, Tanigawara Y, Kaku M, et al. Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:3763-3769.
118. Landman D, Babu E, Shah N, et al. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J Antimicrob Chemother 2010; 65:2123-2127.
119. Landman D, Kelly P, Backer M, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 2011; 66:332-334.
120. Endimiani A, Hujer KM, Hujer AM, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009; 53:4504-4507.
121. Livermore D, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011; 66:48-53.
122. Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the nextgeneration aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infective Ther 2012; 10:459-473.